Future efforts should focus on developing safer, novel, and precision therapeutic strategies to target PCSK9, either independently or in conjunction with existing therapies for the treatment of CVDs, liver diseases, infections, autoimmune disorders, neurocognitive disorders, cancers, and etc. This evidence concerns the gene PCSK9 and liver disorder.